Minocycline as add-on treatment decreases the negative symptoms of schizophrenia; a randomized placebo-controlled clinical trial

Recent Patents on Inflammation and Allergy Drug Discovery

Volumn 8, Issue 3, 2014, Pages 211-215

  Ghanizadeh, Ahmad ^a,b   Dehbozorgi, Sara ^a   OmraniSigaroodi, Motahhar ^a   Rezaei, Zahra ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Catatonic symptoms; Inflammation; Minocycline; Schizophrenia; Tetracycline; Therapeutic

Indexed keywords

MINOCYCLINE; PLACEBO; RISPERIDONE; TETRACYCLINE; ANTIINFECTIVE AGENT; NEUROLEPTIC AGENT;

ABNORMAL INVOLUNTARY MOVEMENT SCALE; ADD ON THERAPY; ADJUVANT THERAPY; ADULT; ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; FEMALE; HUMAN; MALE; NEGATIVE SYNDROME; POSITIVE AND NEGATIVE SYNDROME SCALE; RANDOMIZED CONTROLLED TRIAL; SCALE FOR ASSESSMENT OF NEGATIVE SYMPTOM; SCHIZOPHRENIA; SCHIZOPHRENIA ASSESSMENT; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; PATENT; PATHOPHYSIOLOGY; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTI-BACTERIAL AGENTS; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MINOCYCLINE; PATENTS AS TOPIC; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84920609519     PISSN: 1872213X     EISSN: 22122710     Source Type: Journal    
DOI: 10.2174/1872213X08666141029123524     Document Type: Article

References (28)

1. Hanson E, Healey K, Wolf D, Kohler C. Assessment of pharmacotherapy for negative symptoms of schizophrenia. Curr Psychiatry Rep 2010; 12(6): 563-71.
2. Miyaoka T. Clinical potential of minocycline for schizophrenia. CNS Neurol Disord Drug Targets 2008; 7(4): 376-81.
3. Chaves C, Marque CR, Trzesniak C, Machado de Sousa JP, Zuardi AW, Crippa JA, et al. Glutamate-N-methyl-D-aspartate receptor modulation and minocycline for the treatment of patients with schizophrenia: An update. Braz J Med Biol Res 2009; 42(11): 1002-14.
4. Levkovitz Y, Levi U, Braw Y, Cohen H. Minocycline, a secondgeneration tetracycline, as a neuroprotective agent in an animal model of schizophrenia. Brain Res 2007; 1154: 154-62.
5. Liaury K, Miyaoka T, Tsumori T, Furuya M, Hashioka S, Wake R, et al. Minocycline improves recognition memory and attenuates microglial activation in Gunn rat: A possible hyperbilirubinemiainduced animal model of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2014; 50: 184-90.
6. Monte AS, de Souza GC, McIntyre RS, Soczynska JK, dos Santos JV, Cordeiro RC, et al. Prevention and reversal of ketamineinduced schizophrenia related behavior by minocycline in mice: Possible involvement of antioxidant and nitrergic pathways. J Psychopharmacol 2013; 27(11): 1032-43.
7. Seki Y, Kato TA, Monji A, Mizoguchi Y, Horikawa H, Sato-Kasai M Y, et al. Pretreatment of aripiprazole and minocycline, but not haloperidol, suppresses oligodendrocyte damage from interferongamma-stimulated microglia in co-culture model. Schizophr Res 2013; 151(1-3): 20-8.
8. Miyaoka T, Yasukawa R, Yasuda H, Hayashida M, Inagaki T, Horiguchi J. Possible antipsychotic effects of minocycline in patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31(1): 304-7.
9. Jhamnani K, Shivakumar V, Kalmady S, Rao NP, Venkatasubramanian G. Successful use of add-on minocycline for treatment of persistent negative symptoms in schizophrenia. J Neuropsychiatry Clin Neurosci 2013; 25(1): E06-7.
10. Kelly DL, Vyas G, Richardson CM, Koola M, McMahon RP, Buchanan RW, et al. Adjunct minocycline to clozapine treated patients with persistent schizophrenia symptoms. Schizophr Res 2011; 133(1-3): 257-8.
11. Miyaoka T, Yasukawa R, Yasuda H, Hayashida M, Inagaki T, Horiguchi J. Minocycline as adjunctive therapy for schizophrenia: An open-label study. Clin Neuropharmacol 2008; 31(5): 287-92.
12. Chaudhry IB, Hallak J, Husain N, Minhas F, Stirling J, Richardson P, et al. Minocycline benefits negative symptoms in early schizophrenia: A randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J Psychopharmacol 2012; 26(9): 1185-93.
13. Khodaie-Ardakani MR, Mirshafiee O, Farokhnia M, Tajdini M, Hosseini SM, Modabbernia A, et al. Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: Randomized double-blind placebo-controlled study. Psychiatry Res 2014; 215(3): 540-6.
14. Levkovitz Y, Mendlovich S, Riwkes S, Braw Y, Levkovitch-Verbin H, Gal G, et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry 2010; 71(2): 138-49.
15. Sommer IE, van Westrhenen R, Begemann MJ, de Witte LD, Leucht S, Kahn RS, et al. Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: An update. Schizophr Bull 2014; 40(1): 181-91.
16. Andreasen NC. The Scale for the Assessment of Negative Symptoms (SANS). University of Iowa: Iowa City 1983.
17. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13(2): 261-76.
18. Beck AT, Alford BA. Depression: Causes and treatments. University of Pennsylvania Press: Pennsylvania 2009.
19. Rush AJ. Handbook of psychiatric measures. American Psychiatric Association: Washington 2000.
20. Ahuja N, Carroll BT. Possible anti-catatonic effects of minocycline in patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31(4): 968-9.
21. Shlomo, M., Yechiel, L. Combined therapies of antipsychotic drugs and tetracyclines in the treatment of psychiatric disorders. US20130190275 (2013).
22. Vrudhula, V.M., Pan, S., Rajamani, R., Macor, J.E., Bronson, J.J., Dzierba, C.D., Nara, S.J., Karatholuvhu, M.S. Aryl ether-base kinase inhibitors. US20140179725 (2014).
23. Levy, S.B., Draper, M., Nelson, M.L., Jones, G. Tetracycline compound exhibiting target-treating activity. JP2011057693 (2011).
24. Marconnet-Decrane, L.F.B., Gaurrand, S.F.D., Angibaud, P.R. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase. US8664223 (2014).
25. Verdonck, M.G.C., Angibaud, P.R., Roux, B., Pilatte, I.N.C., Ten Holte, P., Arts, J., Van Emelen, K. Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase. US8592441 (2013).
26. Ghanizadeh A, Omrani Sigaroodi M, Javadpour A, Dabbaghmanesh MH, Shafiee S. Lovastatin as an adjuvant to lithium for treating manic phase of bipolar disorder: A 4-week, randomized, double-blind, placebo-controlled clinical trial. Depress Res Treat 2014; 2014: 730505. doi: 10.1155/2014/730505.
27. Ghanizadeh A, Rezaee Z, Dehbozorgi S, Berk M, Akhondzadeh S. Lovastatin for the adjunctive treatment of schizophrenia: A preliminary randomized double-blind placebo-controlled trial. Psychiatry Res 2014; 219(3): 431-5.
28. Ghanizadeh A, Berk M. Molecular hydrogen: An overview of its neurobiological effects and therapeutic potential for bipolar disorder and schizophrenia. Med Gas Res 2013; 3(1): 11. doi: 10.1186/2045-9912-3-11.